Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention*

Size: px
Start display at page:

Download "Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention*"

Transcription

1 CHEST Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention* The Need for Consensus and a Management Guideline Gregory Y. H. Lip, MD; and Manas Karpha, MB Original Research ANTITHROMBOTIC THERAPY Background: There is a lack of published evidence on what is the optimal management strategy in anticoagulated patients with nonvalvular atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) and, hence, need antiplatelet therapy. Aims: Review of cases of patients with nonvalvular AF undergoing PCI in our hospital, either as an elective case or following acute coronary syndrome (ACS). Methods: By means of our local West Midlands Regional Health Authority computerized Hospital Activity Analysis register, we obtained a list of all patients seen at our hospital with a diagnosis of AF in association with ACS or PCI between 2000 and Patient clinical details and antithrombotic therapy management during PCI were recorded. Results: Of the drugs prescribed on discharge, aspirin and clopidogrel were prescribed to 25 patients (71.4%), while 6 patients (17.1%) were discharged receiving triple therapy, 2 patients (5.7%) receiving clopidogrel alone, and 2 patients (5.7%) receiving warfarin plus one antiplatelet drug (either aspirin or clopidogrel). There was wide variability in the antithrombotic regime and duration of treatment used by the four interventionists in our unit. Conclusion: This case series reveals the lack of any coordinated strategy in the prevention of thrombotic or thromboembolic events in patients with AF and a recent PCI. Further large studies are required to assess the bleeding and thrombotic risk with various post-pci strategies in order to facilitate the development of guidelines. Suggested management guidelines are made in this article. (CHEST 2006; 130: ) Key words: acute coronary syndrome; anticoagulation; antiplatelet; atrial fibrillation; percutaneous coronary intervention Abbreviations: ACS acute coronary syndrome; AF atrial fibrillation; ICD-10 International Classification of Diseases, Tenth Revision; INR international normalized ratio; PCI percutaneous coronary intervention; WARIS-II Warfarin, Aspirin, Reinfarction Study Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its association with cardiovascular disease or its risk factors is well recognized. In *From the Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK. Dr. Lip has received funding for research, educational symposia, consultancy, and lecturing from different manufacturers of drugs used for the treatment of AF and thrombosis. He is Clinical Adviser to the Guideline Development Group writing the United Kingdom National Institute for Health and Clinical Excellence guidelines on AF management ( and is a contributor to the American College of Chest Physicians Consensus Guidelines on Antithrombotic Therapy. Dr. Karpha has no conflicts of interest to disclose. high-risk patients with nonvalvular AF, anticoagulation with warfarin is recommended to reduce the risk of stroke and thromboembolic events. 1 In patients with coronary artery disease, treatment with aspirin Manuscript received July 12, 2006; revision accepted August 16, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Gregory Y. H. Lip, MD; City Hospital, Dudley Rd, Birmingham, B18 7QH, UK; g.y.h.lip@bham.ac.uk DOI: /chest CHEST / 130 / 6/ DECEMBER,

2 and/or clopidogrel is recommended for cardiovascular prevention 2 ; following presentation with an acute coronary syndrome (ACS), or with coronary stent insertion, combination aspirin-clopidogrel therapy is recommended. 3,4 The duration of dual antiplatelet therapy also varies, ranging from 4 weeks following bare metal stent implantation during elective angioplasty, to 6 to 12 months with drug-eluting stents, in view of the risk of late stent thrombosis. 4 Warfarin monotherapy is a poor therapeutic choice after bare metal stenting, with a high rate of adverse cardiac complications after stent implantation. 5 However, in patients with coronary artery disease, anticoagulation with warfarin may provide a similar degree of vascular protection to antiplatelet therapy, at least in post-acs or post-myocardial infarction settings. 6,7 Many patients with AF have associated coronary artery disease. Common clinical practice is to coprescribe low-dose aspirin (eg, 75 mg/d) with warfarin, when it is used, on the assumption that aspirin and warfarin act on differing aspects of the thrombotic pathway. Many contemporary clinical trials of anticoagulation in AF have even allowed concomitant use of aspirin to doses 100 mg/d. 8 However, the use of aspirin plus warfarin or triple therapy (aspirin, clopidogrel, plus warfarin) is recognized to be associated with more bleeding complications. 6,7 There is a lack of published evidence on what is the optimal management strategy in anticoagulated AF patients who undergo percutaneous coronary intervention (PCI) and hence need antiplatelet therapy. Current clinical guidelines on antithrombotic therapy use in AF do not adequately address this issue. The recent UK National Institute for Health and Clinical Excellence clinical guidelines 9 on AF management noted that the addition of aspirin to oral anticoagulation produced no extra benefit for stroke prevention but increased bleeding risk and recommended that for stroke prevention in AF, aspirin should not be administered as adjunctive therapy to warfarin. It was considered a matter for clinical judgement on the appropriateness, duration, and safety (eg, risk of bleeding) of the concomitant administration of warfarin with aspirin, for example, in the setting of vascular disease. The extent to which the lack of evidence or guidelines is problematic in the UK setting is unknown. We are aware of one retrospective US case series 10 that reported safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in 66 patients with an indication for anticoagulation, where 6 patients (9.2%) sustained a bleeding event. In this article, we present a case series of patients with nonvalvular AF undergoing PCI in our hospital, either as an elective case or following ACS. More importantly, we also try to make some suggestions on the rational management of this clinical scenario, based on the perceived risk of bleeding and the clinical setting (ACS/non-ACS), drawing on the limited data available from different clinical studies in diverse patient groups. Materials and Methods City Hospital, Birmingham is a city-center teaching hospital serving a catchment population of 350,000. There are five cardiologists based in this hospital, four of whom perform PCI. By means of our local West Midlands Regional Health Authority computerized Hospital Activity Analysis register, we obtained a list of all patients seen at our hospital with a diagnosis of AF (International Classification of Diseases, Tenth Revision [ICD- 10] code I48), in association with ACS (ICD-10 codes I20/I21/ I22) or PCI (ICD-10 codes K498/Y022) from 2000 to This coding system has been proved free of errors for definitive diagnoses, 11 although errors are found in the coding of nonspecific diagnoses such as viral infections or gastroenteritis. To minimize any inaccuracies in coding, we also inspected the case notes and cross-referenced with our computerized PCI database that records our PCI activity for annual returns to the British Coronary Intervention Society. Patient clinical details and antithrombotic therapy management during PCI were recorded. For inclusion in this case series, patients could have a preexisting diagnosis of AF, or new-onset AF could have developed in the setting of the current acute admission (usually with an ACS). There is a proactive revascularization strategy in place in our unit, in which the majority of patients presenting with an ACS undergo diagnostic cardiac catheterization with a view to PCI within 48 to 72 h of admission. Individual patient management decisions were left to the discretion of the responsible cardiologist. Results From 2000 to 2005, 1,234 PCIs were performed at our hospital. A total of 35 patients (2.8%) with AF were identified. (Full details of individual patients are provided in a Web-only supplementary Table.) Nineteen patients had preexisting AF, while newonset AF developed in 16 patients following admission. The mean age of our population was 71 years (range, 50 to 91 years). Of the whole cohort, 22 patients (62.9%) had a previous history of ischemic heart disease, 12 patients (34.3%) were diabetic, and 23 patients (65.7%) were hypertensive. Drug therapy at the time of hospital admission consisted of warfarin in 11 patients (31.4%), aspirin in 13 patients (37.1%), and clopidogrel in 5 patients (14.3%), while 6 patients (17.1%) were receiving no anticoagulants/antiplatelets. Of those with previously known AF (n 19), 11 patients were receiving warfarin, 5 were receiving aspirin, 2 were receiving clopidogrel, and 1 patient was receiving no antithrombotic therapy. The majority of patients (65.7%) were treated with a low-molecular-weight heparin in addition to aspirin-clopidogrel therapy on admission. All patients receiving warfarin had this discontinued on admission prior to PCI. At the time of hospital discharge, aspirin and clopi Original Research

3 dogrel were prescribed to 25 patients (71.4%), while 6 patients (17.1%) were discharged receiving triple therapy, 2 patients (5.7%) receiving clopidogrel alone, and 2 patients (5.7%) receiving warfarin plus one antiplatelet drug (either aspirin or clopidogrel). The majority of our patients had their duration of treatment documented in the notes, but there was wide variability in the antithrombotic therapy regime and duration of treatment used by the four interventionists in our unit. A total of 10 patients were administered 1 year of clopidogrel with lifelong aspirin, and 4 patients were treated with aspirin and clopidogrel lifelong. In the whole cohort, eight patients were told to stop one of their antiplatelet drugs after either 1, 3, 4, or 12 months, replacing it with warfarin. In two patients, it was not possible to determine their duration of therapy from the notes. Management of Patients Receiving Warfarin Before PCI Of the 11 patients admitted who were receiving warfarin, 6 patients had their warfarin restarted at some point in their follow-up when an antiplatelet was stopped (patients 7, 8, 10, 13, 16, and 18) [Web-only supplementary Table]. Two patients had their warfarin stopped (patients 5 and 6), and one other patient had warfarin stopped following PCI in 2000 but was seen in clinic and had warfarin restarted in 2006 (patient 11). One patient was planned to receive warfarin for 3 months but died after PCI (patient 17). One patient was discharged receiving warfarin and clopidogrel with no duration documented in the notes; unfortunately, she died 2 months later with acute renal failure and sepsis (patient 19). Patients Discharged Receiving Triple Therapy Of the patients discharged receiving triple therapy, again there was no consistency in the duration of treatment, with either warfarin or one antiplatelet agent being stopped from 1 to 3 months following PCI, which was performed using bare metal stents. There were no bleeding complications requiring hospitalization at 30-day follow-up. At follow-up (up to 1 year), one patient who was discharged receiving aspirin and clopidogrel only was admitted to hospital with rectal bleeding and anemia. Discussion Our case series highlights the variability in the use of anticoagulant/antiplatelet therapy in patients undergoing PCI who have AF. Although the combination of aspirin and clopidogrel accounted for the majority of patients (71.4%), the duration of their use still varied widely among patients. The use of triple therapy was relatively low among these patients due to the concerns of life-threatening bleeding. This variability of post-pci prescription is understandable in light of the lack of guidelines available. It has been suggested that the post-pci strategy should be tailored to the individual patient and their risk of thromboembolism and stent thrombosis against their risk of bleeding while receiving triple therapy. 12 For example, in patients with lone AF (who would not normally be prescribed warfarin, especially if aged 65 years), dual antiplatelet therapy after PCI should be used, with a view to stopping clopidogrel after 4 weeks for bare metal stents or 6 to 12 months for drug-eluting stents, in view of the risk of late stent thrombosis with the latter. 4 If other stroke risk factors have been identified, notably hypertension or diabetes, then the clopidogrel should be continued indefinitely or changed to warfarin after 4 weeks. Another strategy suggested the continuous use of triple therapy (warfarin, aspirin plus clopidogrel) since aspirin-clopidogrel therapy is recommended after ACS for up to 12 months but keeping the international normalized ratio (INR) target value in the lower therapeutic range. 13 However, these suggestions are, as described, just suggestions and not evidence-based guidelines. Our own suggestions for management guidelines in this setting are summarized in Table 1. These make certain assumptions, and are (very) limited by extrapolation of evidence from diverse observations from different clinical studies, in different settings. Firstly, anticoagulation is a reasonable strategy in ACS 6,14 and may be an alternative to aspirin, as evident by some clinical trials, such as the Warfarin, Aspirin, Reinfarction Study (WARIS-II). 6,7 Secondly, the main benefit of aspirin after myocardial infarction is seen in the first 35 days, with little further mortality benefit or loss during subsequent years. 15 In ACS patients, there is evidence of a benefit of aspirin-clopidogrel use for up to 9 months, as shown in the Clopidogrel in Unstable Angina To Prevent Recurrent Events study 16 (and the Clopidogrel in Unstable Angina To Prevent Recurrent Events-PCI study 17 ), but the benefit seen (death from cardiovascular causes, nonfatal myocardial infarction, or stroke occurred in 9.3% of the clopidogrel group vs 11.4% in the placebo group) needs to be put in context with the increased risk of bleeding (3.7% in the clopidogrel group vs 2.7% in the placebo group) with combination aspirin-clopidogrel therapy In the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial, 19 clopidogrel (75 mg/d) plus aspirin (75 to 162 mg/d) was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes in 15,603 patients CHEST / 130 / 6/ DECEMBER,

4 Table 1 Suggested Management Strategy for Patients With Nonvalvular AF Requiring Anticoagulation and PCI With Stenting* Stroke Risk Category Usual Strategy Recommended Perceived Potential Bleeding Risk ACS Presentation Post-PCI Management Low Aspirin Bare metal stent: aspirin plus clopidogrel for 4 wk, then aspirin. Drugeluting stent: aspirin plus clopidogrel for 6 to 12 mo, then aspirin. High Warfarin Low No Use bare metal stent if possible. Bare metal stent: triple therapy with warfarin, aspirin plus clopidogrel for 2 to 4 wks; then change to warfarin plus clopidogrel for up to month 12; then warfarin alone. Drug-eluting stent: triple therapy with warfarin, aspirin, and clopidogrel from 3 6 (or more) mo; then warfarin plus clopidogrel for up to month 12; then warfarin alone. Low Yes Bare metal stent or drug-eluting stent: triple therapy with warfarin, aspirin, and clopidogrel from 3 6 (or more) mo; then warfarin plus clopidogrel for up to month 12; then warfarin alone. High Warfarin High No Use bare metal stent if possible. Bare metal stent: triple therapy with warfarin, aspirin plus clopidogrel for 4 wk; then change to warfarin alone. Drug-eluting stent: triple therapy with warfarin, aspirin, and clopidogrel for 4 wk; then warfarin plus clopidogrel for up to month 12; then warfarin alone. High Yes Bare metal stent or drug-eluting stent: triple therapy with warfarin, aspirin, and clopidogrel for 4 wk; then warfarin plus clopidogrel for up to month 12; then warfarin alone. *Doses: aspirin, 75 to 81 mg/d; clopidogrel, 75 mg/d. Warfarin is dose adjusted to target INR of 2.0 to 2.5. Particular attention paid to the following risk factors: (1) patients who are 75 yr old; (2) patients receiving nonsteroidal anti-inflammatory drugs; (3) patients receiving multiple other drug treatments (polypharmacy); (4) patients with uncontrolled hypertension; (5) patients with a history of bleeding (for example, peptic ulcer or cerebral hemorrhage); and (6) patients with a history of poorly controlled anticoagulation therapy. with either clinically evident cardiovascular disease or multiple risk factors, with an increase in moderate-tosevere bleeding. There is also a very well-argued analysis that clopidogrel therapy beyond a few months after PCI does not influence mortality, has a questionable effect on the incidence of myocardial infarction, and is not cost-effective, but results in a significant increase in major bleeding. 18 In contrast to clopidogrel, aspirin may have more direct effects on the gastric mucosa, leading to erosions and bleeding; however, one recent analysis 20 among patients with a history of aspirin-induced ulcer bleeding whose ulcers had healed, aspirin plus esomeprazole (a proton-pump inhibitor) was superior to clopidogrel in the prevention of recurrent ulcer bleeding. In the WARIS-II trial, 7 warfarin plus aspirin was not significant different to warfarin alone after myocardial infarction in reducing the composite end point of death, nonfatal reinfarction, or thromboembolic cerebral stroke, but a more recent metaanalysis 21 (which included the WARIS-II data) found that for patients recovering from ACS, a combined strategy of aspirin plus warfarin at INR values of 2 to 3 was superior to aspirin alone in preventing major adverse events (all-cause death, nonfatal myocardial infarction, and nonfatal thromboembolic stroke) but doubled the risk of major bleeds. Given the risk of bleeding of warfarin plus aspirin, we have made the recommendation of warfarin plus clopidogrel in Table 1, but whether this combined regimen is also superior to triple therapy (warfarin plus double antiplatelet strategy) or to newer evolving treatments, or safer in terms of bleeding risk (especially with the use of a protonpump inhibitor), warrants further investigation. Of note, aspirin-clopidogrel was a poor strategy for stroke prevention in high-risk patients with AF, as shown in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events Trial. 22 Clearly, a balance is needed between stroke and cardiac event prevention, as well as bleeding risks. Indeed, a recent metaanalysis 23 with estimates of risk and benefit of warfarin plus aspirin after myocardial infarction or ACS reviewed 10 trials involving a total of 5,938 patients (11,334 patient-years) concluded that for patients who are at low or intermediate risk for bleeding, the cardiovascular benefits of warfarin outweigh the bleeding risks. However, this metaanalysis reviewed studies that did not include coronary stenting, and results therefore may not be applicable to patients with stents. Nonetheless, the real-life bleeding complications associated with combinations of aspirin, thienopyridine derivatives (clopidogrel or ticlopidine) and 1826 Original Research

5 warfarin in elderly patients following acute myocardial infarction is only modestly increased and the overall risk may be small, 24 as shown in our small cases series. The utility of bleeding risk stratification schemes for anticoagulated patients with AF also requires further prospective data. 25 Although limited by the experience of a single center, this case series reveals the lack of any coordinated strategy in the prevention of thrombotic or thromboembolic events in patients with AF and a recent PCI. Further large studies are required to assess the bleeding and thrombotic risk with various post-pci strategies in patients with AF, in order to facilitate the development of guidelines. As AF is common in patients with coronary artery disease, the need to make an informed decision in the long-term strategy of these patients is a commonplace clinical scenario affecting many physicians in today s clinical practice. References 1 Lip GYH, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006; 92: JBS 2: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice Prepared by: British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. Heart 2005; 91(Suppl 5):v1 v52 3 Bertrand ME, Simoons ML, Fox KA, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: Task Force for Percutaneous Coronary Intervention of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26: Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: Lip GYH, Varma C. Anticoagulation plus aspirin following acute myocardial infarction: yes or no... and if the latter, why not? Thromb Res 2006; 118: Hurlen M, Abdelnorr M, Smith P, et al. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002; 347: Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London, UK: Royal College of Physicians, Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J. 2004; 147: George LM, Maddock K. Accuracy of hospital activity notifications for infectious diseases. Br Med J 1979; 1: Wong EML, Wu EB, Chan WWM, et al. A review of the management of patients after percutaneous coronary intervention. Int J Clin Pract 2006; 60: Schneider H, Weber F, Holzhausen C, et al. Dual antithrombotic therapy after implantation of coronary stents. Dtsch Med Wochenschr 2006; 131: Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003; 362: Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of IV streptokinase, oral aspirin, both, or neither; The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998; 316: The Clopidogrel in Unstable Angina To Prevent Recurrent Events (CURE) Trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the emperor s new clothes revisited. Eur Heart J 2004; 25: Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin vs aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: Chan FK, Ching JY, Hung LC, et al. Clopidogrel vs aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005; 352: Andreotti F, Testa L, Biondi-Zoccai GG, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27: Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005; 165: Kakar P, Lane D, Lip GYH. Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest 2006; 130: CHEST / 130 / 6/ DECEMBER,

Journal of the American College of Cardiology Vol. 51, No. 8, by the American College of Cardiology Foundation ISSN /08/$34.

Journal of the American College of Cardiology Vol. 51, No. 8, by the American College of Cardiology Foundation ISSN /08/$34. Journal of the American College of Cardiology Vol. 51, No. 8, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.11.035

More information

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy

More information

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,

More information

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck. DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets

More information

Scope of the Problem: DAPT and Triple Therapy after Stenting

Scope of the Problem: DAPT and Triple Therapy after Stenting Scope of the Problem: DAPT and Triple Therapy after Stenting Kurt Huber, MD, FESC, FACC 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Session, August 30, 2010,

More information

NeuroPI Case Study: Anticoagulant Therapy

NeuroPI Case Study: Anticoagulant Therapy Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to

More information

NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING

NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS

More information

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013

More information

Preoperative Management of Patients Receiving Antithrombotics

Preoperative Management of Patients Receiving Antithrombotics Preoperative Management of Patients Receiving Antithrombotics Bleeding complications remain an important concern for most surgical procedures. Attempts to minimize the risk of these complications by removing

More information

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals

More information

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate

More information

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)

More information

Dual Antiplatelet Therapy Made Practical

Dual Antiplatelet Therapy Made Practical Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor

More information

2010, Metzler Helfried

2010, Metzler Helfried Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What

More information

Antithrombotic therapy: triple therapy or triple threat?

Antithrombotic therapy: triple therapy or triple threat? THE NEW ERA IN ANTITHROMBOTIC THERAPY Antithrombotic therapy: triple therapy or triple threat? Jessica Mega 1 and Edward T. Carreras 1 1 Brigham and Women s Hospital and Harvard Medical School, Boston,

More information

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients

More information

Secondary Stroke Prevention: A Precautionary Tale

Secondary Stroke Prevention: A Precautionary Tale Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature

More information

Study design: multicenter, randomized, open-label trial following a PROBE design

Study design: multicenter, randomized, open-label trial following a PROBE design Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan

More information

Anti-platelet therapies and dual inhibition in practice

Anti-platelet therapies and dual inhibition in practice Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine

More information

Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease

Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease The Harvard community has made this article openly available. Please share how this access benefits you. Your

More information

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan

More information

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017 GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional

More information

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals. OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral

More information

FastTest. You ve read the book now test yourself

FastTest. You ve read the book now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved

Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved . Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation

More information

Evaluate Risk of Stroke & Bleeding in AF Patients

Evaluate Risk of Stroke & Bleeding in AF Patients XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet

More information

Antiplatelets in cardiac patients with suspected GI bleeding

Antiplatelets in cardiac patients with suspected GI bleeding Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding

More information

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:

More information

American College of Cardiology 66th Annual Scientific Session (ACC.17):

American College of Cardiology 66th Annual Scientific Session (ACC.17): News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

Acute Coronary syndrome

Acute Coronary syndrome Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood

More information

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most

More information

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation

More information

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation

More information

OUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.

OUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R. INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra

More information

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan

More information

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events. ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

More information

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet

More information

APPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL

APPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH

More information

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation

More information

Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto

Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely

Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1

More information

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and

More information

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές 4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος

More information

Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?

Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently

More information

After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy

After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel

More information

NOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB

NOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the

More information

Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine

Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:

More information

The MAIN-COMPARE Study

The MAIN-COMPARE Study Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

Prevention of Coronary Stent Thrombosis and Restenosis

Prevention of Coronary Stent Thrombosis and Restenosis Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Learning Objectives. Epidemiology of Acute Coronary Syndrome Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet

More information

ST Elevated Myocardial Infarction- Latest AHA recommendations

ST Elevated Myocardial Infarction- Latest AHA recommendations ST Elevated Myocardial Infarction- Latest AHA recommendations Sherry Turner, DO, MPH, FACOEP Medical Director Emergency Services Wesley Medical Center The Problem 250,000 Americans each year 30% fail to

More information

Handbook of Oral Anticoagulation Second edition

Handbook of Oral Anticoagulation Second edition Handbook of Oral Anticoagulation Second edition Handbook of Oral Anticoagulation Second edition Editors Gregory YH Lip University of Birmingham Birmingham, UK Eduard Shantsila University of Birmingham

More information

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents

More information

Dental Management Considerations for Patients on Antithrombotic Therapy

Dental Management Considerations for Patients on Antithrombotic Therapy Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Which drug do you prefer for stable CAD? - P2Y12 inhibitor Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,

More information

Oral anti-thrombotic therapy-management in patients requiring endoscopy

Oral anti-thrombotic therapy-management in patients requiring endoscopy Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients

More information

When and how to combine antiplatelet agents and anticoagulant?

When and how to combine antiplatelet agents and anticoagulant? When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation

More information

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology

More information

Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου

Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy

More information

December 20, 2017 Edited by: Gregory K. Perry, PharmD, BCPS-AQID

December 20, 2017 Edited by: Gregory K. Perry, PharmD, BCPS-AQID VOLUME THREE; ISSUE 11 December 20, 2017 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update December 20 th, 2017 Meeting The Pharmacy and Therapeutics

More information

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current

More information

Triple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health

Triple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence

More information

Do Not Cite. Draft for Work Group Review.

Do Not Cite. Draft for Work Group Review. Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted

More information

Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!

Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1

More information

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden

More information

Additional Contributor: Glenn Levine (USA).

Additional Contributor: Glenn Levine (USA). 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management

More information

Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States

Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States Alimentary Pharmacology and Therapeutics Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States R. Casado-Arroyo*,

More information

Am J Gastroenterol 2010;105:

Am J Gastroenterol 2010;105: ACCF/ACG/AHA 2010 Expert Consensus Document Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document

More information

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in

More information

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI) Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension

More information

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel

More information

OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION

OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION FEROZ MEMON*, LIAQUAT CHEEMA**, NAND LAL RATHI***, RAJ KUMAR***, NAZIR AHMED MEMON**** OBJECTIVE: To compare morbidity,

More information

Alberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management

Alberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management Alberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management Assessment Tools and Suggested Management for the Patient on Antithrombotics Undergoing a Screening-Related Colonoscopy Version

More information

Combining Antiplatelet and Anticoagulant Therapies

Combining Antiplatelet and Anticoagulant Therapies Journal of the American College of Cardiology Vol. 54, No. 2, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.044

More information

A Patient with Chest Pain and Atrial Fibrillation

A Patient with Chest Pain and Atrial Fibrillation A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi

More information

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita

More information

Unstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc.

Unstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc. Unstable INR Has Implications for Healthcare Resource Use Janssen Pharmaceuticals, Inc. Stable INR is essential for effective anticoagulation treatment Achieving a stable international normalized ratio

More information

Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy

Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy

More information

Stable CAD, Elective Stenting and AFib

Stable CAD, Elective Stenting and AFib Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School

More information

Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine

Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine Conference Papers in Medicine, Article ID 719, pages http://dx.doi.org/1.1155/13/719 Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic

More information

Timing of Surgery After Percutaneous Coronary Intervention

Timing of Surgery After Percutaneous Coronary Intervention Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet

More information

The randomized study of efficiency and safety of antithrombotic therapy in

The randomized study of efficiency and safety of antithrombotic therapy in .. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%

More information

Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose?

Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson

More information

Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?

Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science

More information

ASA PLAVIX AND PREOPERATIVE OPTIMIZATION. John Hann, MD

ASA PLAVIX AND PREOPERATIVE OPTIMIZATION. John Hann, MD ASA PLAVIX AND PREOPERATIVE OPTIMIZATION John Hann, MD QUESTIONS: WHICH ANTI-PLATELETS DO YOU STOP AND WHEN? 1. 65 yo M with history of stroke on ASA PreOp eval for cataracts surgery 2. 65 yo M with RCRI

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information